Beyond the Mouse

---

“It is important to remember how significant negative selection is in shaping the antibody repertoire; Fifty percent or more of all newly generated B cells are auto-reactive and are subsequently eliminated as a result of tolerance. In addition, since mouse and human proteins can be very homologous, many therapeutically valuable epitopes may be inaccessible to repertoires derived from humans or transgenic animals. The HuTARG technology is available to companies interested in in-licensing a fully human antibody generation technology that provides unbiased, tolerance-free repertoires. Because the technology is a mammalian cell based in vitro technology, extensive infrastructure to support the technology is not required.”

Michael Gallo
President
Innovative Targeting Solutions Inc.